<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK45978" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK45978/" /><meta name="ncbi_pagename" content="Spastic Paraplegia 3A - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Spastic Paraplegia 3A - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="Spastic Paraplegia 3A" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2014/12/11" /><meta name="citation_author" content="Peter Hedera" /><meta name="citation_pmid" content="20862796" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK45978/" /><meta name="citation_keywords" content="SPG3A" /><meta name="citation_keywords" content="SPG3A" /><meta name="citation_keywords" content="Atlastin-1" /><meta name="citation_keywords" content="ATL1" /><meta name="citation_keywords" content="Spastic Paraplegia 3A" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Spastic Paraplegia 3A" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Peter Hedera" /><meta name="DC.Date" content="2014/12/11" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK45978/" /><meta name="description" content="Spastic paraplegia 3A (SPG3A) is a hereditary spastic paraplegia (HSP) characterized by progressive bilateral and mostly symmetric spasticity and weakness of the legs, diminished vibration sense caused by degeneration of the corticospinal tracts and dorsal columns, and urinary bladder hyperactivity. The average age of onset is four years. More than 80% of reported individuals manifest spastic gait before the end of the first decade of life. Most persons with early-onset SPG3A have a &quot;pure&quot; (&quot;uncomplicated&quot;) HSP; however, complicated HSP with axonal motor neuropathy and/or distal amyotrophy with lower motor neuron involvement (Silver syndrome phenotype) have been observed. The rate of progression in SPG3A is slow, and wheelchair dependency or need for a walking aid (cane, walker, or wheelchair) is relatively rare." /><meta name="og:title" content="Spastic Paraplegia 3A" /><meta name="og:type" content="book" /><meta name="og:description" content="Spastic paraplegia 3A (SPG3A) is a hereditary spastic paraplegia (HSP) characterized by progressive bilateral and mostly symmetric spasticity and weakness of the legs, diminished vibration sense caused by degeneration of the corticospinal tracts and dorsal columns, and urinary bladder hyperactivity. The average age of onset is four years. More than 80% of reported individuals manifest spastic gait before the end of the first decade of life. Most persons with early-onset SPG3A have a &quot;pure&quot; (&quot;uncomplicated&quot;) HSP; however, complicated HSP with axonal motor neuropathy and/or distal amyotrophy with lower motor neuron involvement (Silver syndrome phenotype) have been observed. The rate of progression in SPG3A is slow, and wheelchair dependency or need for a walking aid (cane, walker, or wheelchair) is relatively rare." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK45978/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/spg3a/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK45978/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8AC3E6E04243F10000000002F20129.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK45978_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK45978_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/sotos/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/spg4/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK45978_"><span class="title" itemprop="name">Spastic Paraplegia 3A</span></h1><div itemprop="alternativeHeadline" class="subtitle whole_rhythm">Synonym: SPG3A</div><p class="contrib-group"><span itemprop="author">Peter Hedera</span>, MD, PhD.</p><a data-jig="ncbitoggler" href="#__NBK45978_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK45978_ai__"><div class="contrib half_rhythm"><span itemprop="author">Peter Hedera</span>, MD, PhD<div class="affiliation small">Department of Neurology<br />Vanderbilt University<br />Nashville, Tennessee<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.tlibrednav@aredeh.retep" class="oemail">ude.tlibrednav@aredeh.retep</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">September 21, 2010</span>; Last Update: <span itemprop="dateModified">December 11, 2014</span>.</p><p><em>Estimated reading time: 19 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="spg3a.Summary" itemprop="description"><h2 id="_spg3a_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>Spastic paraplegia 3A (SPG3A) is a hereditary spastic paraplegia (HSP) characterized by progressive bilateral and mostly symmetric spasticity and weakness of the legs, diminished vibration sense caused by degeneration of the corticospinal tracts and dorsal columns, and urinary bladder hyperactivity. The average age of onset is four years. More than 80% of reported individuals manifest spastic gait before the end of the first decade of life. Most persons with early-onset SPG3A have a "pure" ("uncomplicated") HSP; however, complicated HSP with axonal motor neuropathy and/or distal amyotrophy with lower motor neuron involvement (Silver syndrome <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>) have been observed. The rate of progression in SPG3A is slow, and wheelchair dependency or need for a walking aid (cane, walker, or wheelchair) is relatively rare.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis of SPG3A can be established only by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> of <i>ATL1,</i> the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> encoding the protein atlastin-1.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> Treatment is symptomatic. Medical treatment of spasticity may begin with oral baclofen or tizanidine, followed by chemodenervation with botulinum A or B toxins if oral antispasticity medications are not tolerated. Intrathecal baclofen pump may be considered for those who improve on oral baclofen but have significant systemic adverse effects. Medical therapy should be combined with intensive physical therapy focused on stretching and strengthening exercises. Distal weakness (typically affecting foot dorsiflexion) can be ameliorated by ankle-foot orthoses. Urinary urgency can be treated with anticholinergic antispasmodic drugs.</p><p><i>Prevention of secondary complications:</i> Muscle tendon contractures, scoliosis, and foot deformities, the most likely secondary complications, may be delayed or minimized with intense and regular physiotherapy for the spasticity.</p><p><i>Surveillance:</i> No consensus exists regarding the frequency of clinical follow up visits, but reevaluation once or twice yearly to identify and treat new complications is recommended.</p><p><i>Agents/circumstances to avoid:</i> Dantrolene, as it can induce irreversible weakness, adversely affecting mobility.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>SPG3A is almost exclusively inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner. More than 95% of individuals diagnosed with SPG3A have an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> parent; however, the proportion of cases caused by a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is currently unknown. Each child of an individual with SPG3A has a 50% chance of inheriting the pathogenic variant. Prenatal diagnosis for pregnancies at increased risk is possible if the pathogenic variant has been identified in the family.</p></div></div><div id="spg3a.Diagnosis"><h2 id="_spg3a_Diagnosis_">Diagnosis</h2><div id="spg3a.Clinical_Diagnosis"><h3>Clinical Diagnosis</h3><p>Spastic paraplegia 3A (SPG3A) is one of the hereditary spastic paraplegias (HSPs), a group of neurodegenerative disorders characterized by progressive bilateral and mostly symmetric lower extremity weakness and spasticity resulting from axonal degeneration of corticospinal tracts, diminished vibration sense caused by impairment of dorsal columns, and urinary bladder hyperactivity.</p><p>Because of the significant overlap between the age of onset and severity of disease among the various genetic types of HSP (see <a href="/books/n/gene/hsp/">Hereditary Spastic Paraplegia</a>), the diagnosis of SPG3A can be established only by molecular testing of <i>ATL1,</i> the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> associated with SPG3A.</p></div><div id="spg3a.Molecular_Genetic_Testing"><h3>Molecular Genetic Testing</h3><p><b>Gene.</b>
<i>ATL1</i> (formerly known as <i>SPG3A</i>)<i>,</i> encoding the protein atlastin-1, is the only <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> known to be associated with spastic paraplegia 3A.</p><div id="spg3a.T.molecular_genetic_testing_used_i" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in Spastic Paraplegia 3A</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK45978/table/spg3a.T.molecular_genetic_testing_used_i/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__spg3a.T.molecular_genetic_testing_used_i_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_spg3a.T.molecular_genetic_testing_used_i_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_spg3a.T.molecular_genetic_testing_used_i_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Test Method</th><th id="hd_h_spg3a.T.molecular_genetic_testing_used_i_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Proportion of Probands with a Pathogenic Variant Detectable by This Method</th></tr></thead><tbody><tr><td headers="hd_h_spg3a.T.molecular_genetic_testing_used_i_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>ATL1</i></td><td headers="hd_h_spg3a.T.molecular_genetic_testing_used_i_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>2,&#x000a0;3</sup></td><td headers="hd_h_spg3a.T.molecular_genetic_testing_used_i_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~100%</td></tr><tr><td headers="hd_h_spg3a.T.molecular_genetic_testing_used_i_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Deletion/<a class="def" href="/books/n/gene/glossary/def-item/duplication/">duplication</a> analysis&#x000a0;<sup>4,&#x000a0;5</sup></td><td headers="hd_h_spg3a.T.molecular_genetic_testing_used_i_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003c;1%</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="spg3a.TF.1.1"><p class="no_margin">See <a href="/books/NBK45978/#spg3a.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein. See <a href="#spg3a.Molecular_Genetics">Molecular Genetics </a>for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>2. </dt><dd><div id="spg3a.TF.1.2"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>3. </dt><dd><div id="spg3a.TF.1.3"><p class="no_margin">Sequence analysis and scanning of the entire <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> for pathogenic variants can have similar variant detection frequencies; however, variant detection rates for scanning may vary considerably between laboratories depending on the specific protocol used.</p></div></dd><dt>4. </dt><dd><div id="spg3a.TF.1.4"><p class="no_margin">Testing that identifies <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications not detectable by <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> of the coding and flanking <a class="def" href="/books/n/gene/glossary/def-item/intronic/">intronic</a> regions of <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> DNA. Methods used may include: <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and <a class="def" href="/books/n/gene/glossary/def-item/chromosomal-microarray/">chromosomal microarray</a> (CMA) that includes this gene/<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> segment.</p></div></dd><dt>5. </dt><dd><div id="spg3a.TF.1.5"><p class="no_margin">Single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or multiexon deletions in <i>ATL1</i> are rare; only one single-exon <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> has been reported to date [<a class="bk_pop" href="#spg3a.REF.sulek.2013.239">Sulek et al 2013</a>].</p></div></dd></dl></div></div></div><p><b>Interpretation of test results.</b> Failure to detect a pathogenic <i>ATL1</i> sequence variant does not absolutely exclude the diagnosis of SPG3A because the frequency of pathogenic variants involving non-coding regions (introns and <a class="def" href="/books/n/gene/glossary/def-item/promoter-region/">promoter region</a>) is unknown.</p></div><div id="spg3a.Testing_Strategy"><h3>Testing Strategy</h3><p><b>To confirm/establish the diagnosis in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>Genotype/<a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> correlation in persons with hereditary spastic paraplegia (HSP) has a low <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a>; the diagnosis of SPG3A can be established only by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>.</div></li><li class="half_rhythm"><div>The yield of <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> of <i>ATL1</i> in individuals who represent <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> cases (i.e., a single occurrence in a family) is unknown, but molecular genetic testing should be considered if acquired causes of spastic paraparesis have been ruled out [<a class="bk_pop" href="#spg3a.REF.rainier.2006.445">Rainier et al 2006</a>].</div></li></ul><p><b>One genetic testing strategy</b> is <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> of <i>ATL.</i></p><ul><li class="half_rhythm"><div>Sequence analysis should be performed first.</div></li><li class="half_rhythm"><div>If no <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is found through <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> can be considered.</div></li></ul><p><b>An alternative genetic testing strategy</b> is use of a <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a> that includes <i>ATL1</i> and other genes of interest (see <a href="#spg3a.Differential_Diagnosis">Differential Diagnosis</a>). Note: (1) The genes included in the panel and the diagnostic <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the testing used for each <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>; thus, clinicians need to determine which multigene panel is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> and pathogenic variants in genes that do not explain the underlying <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused <a class="def" href="/books/n/gene/glossary/def-item/exome/">exome</a> analysis that includes genes specified by the clinician. (4) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing-based tests.</p><p>For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</p><p><b>More comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b> (when available) including <a class="def" href="/books/n/gene/glossary/def-item/exome-sequencing/">exome sequencing</a>, <a class="def" href="/books/n/gene/glossary/def-item/genome-sequencing/">genome sequencing</a>, and mitochondrial sequencing may be considered if single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing (and/or use of a <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a>) fails to confirm a diagnosis in an individual with features of SPG3A.</p><p>For an introduction to comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing click <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing">here</a>. More detailed information for clinicians ordering genomic testing can be found <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing_1">here</a>.</p></div></div><div id="spg3a.Clinical_Characteristics"><h2 id="_spg3a_Clinical_Characteristics_">Clinical Characteristics</h2><div id="spg3a.Clinical_Description"><h3>Clinical Description</h3><p>Spastic paraplegia 3A (SPG3A) is characterized by clinical findings that tend to be more homogeneous than other forms of AD HSP [<a class="bk_pop" href="#spg3a.REF.zhao.2001.326">Zhao et al 2001</a>, <a class="bk_pop" href="#spg3a.REF.d_rr.2004.1867">D&#x000fc;rr et al 2004</a>, <a class="bk_pop" href="#spg3a.REF.hedera.2004.1600">Hedera et al 2004</a>]. The average age of onset is four years. More than 80% of reported individuals manifest spastic gait before the end of the first decade of life. The rate of progression is slow; wheelchair dependency or need for an assistive walking device is relatively rare.</p><p>Although it has been suggested that SPG3A is a neurodevelopmental rather than a neurodegenerative disorder, recent identification of individuals with adult-onset SPG3A argues strongly against this hypothesis [<a class="bk_pop" href="#spg3a.REF.sauter.2004.98">Sauter et al 2004</a>, <a class="bk_pop" href="#spg3a.REF.zhu.2006.1343">Zhu et al 2006</a>]. Persons with adult onset of SPG3A also tend to experience slower progression of their clinical symptoms.</p><p>Most persons with early-onset SPG3A have a "pure" or "uncomplicated" HSP <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. However, complex HSP phenotypes with axonal motor neuropathy and/or distal amyotrophy (like that observed in the Silver syndrome phenotype) have also been reported [<a class="bk_pop" href="#spg3a.REF.scarano.2005.901">Scarano et al 2005</a>, <a class="bk_pop" href="#spg3a.REF.ivanova.2007.706">Ivanova et al 2007</a>, <a class="bk_pop" href="#spg3a.REF.salameh.2009.57">Salameh et al 2009</a>].</p><p>Signs seen less frequently in SPG3A than in other HSPs include the following [<a class="bk_pop" href="#spg3a.REF.d_rr.2004.1867">D&#x000fc;rr et al 2004</a>]:</p><ul><li class="half_rhythm"><div>Hyperreflexia of the upper extremities</div></li><li class="half_rhythm"><div>Impairment of vibration sensation at the ankles</div></li><li class="half_rhythm"><div>Urinary sphincter hyperactivity</div></li></ul><p>Signs seen more frequently in SPG3A than in other HSPs are pes cavus deformities and scoliosis; however, the presence of these findings may be attributable to the earlier age of onset rather than the specific form of HSP.</p></div><div id="spg3a.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p>Most persons with pathogenic variants in <i>ATL1</i> and early-onset disease have pathogenic <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants clustered around the GTPase binding <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a>.</p><p>While some <i>ATL1</i> pathogenic variants associated with late-onset HSP are insertional variants in the C-terminus of the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> that result in a premature truncation of the protein, adult-onset disease has also been observed with <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants in the GTPase binding <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> [<a class="bk_pop" href="#spg3a.REF.tessa.2002.2002">Tessa et al 2002</a>, <a class="bk_pop" href="#spg3a.REF.sauter.2004.98">Sauter et al 2004</a>].</p></div><div id="spg3a.Penetrance"><h3>Penetrance</h3><p>Overall, <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> of pathogenic variants is high (~80%-90%) [<a class="bk_pop" href="#spg3a.REF.d_rr.2004.1867">D&#x000fc;rr et al 2004</a>]. In many <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> cases, individuals with an <i>ATL1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> had a normal neurologic examination even at an advanced age, arguing against significant age-dependent penetrance [<a class="bk_pop" href="#spg3a.REF.d_rr.2004.1867">D&#x000fc;rr et al 2004</a>].</p><p>The lowest <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a>, 30%, was reported for the <a class="figpopup" href="/books/NBK45978/table/spg3a.T.selected_atl1_pathogenic_variant/?report=objectonly" target="object" rid-figpopup="figspg3aTselectedatl1pathogenicvariant" rid-ob="figobspg3aTselectedatl1pathogenicvariant">p.Arg415Trp</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> [<a class="bk_pop" href="#spg3a.REF.damico.2004.2138">D'Amico et al 2004</a>].</p></div><div id="spg3a.Anticipation"><h3>Anticipation</h3><p>Anticipation with an earlier age at onset and increased severity in successive generations is not a feature of the majority of SPG3A kindreds. However, a bias of ascertainment towards earlier recognition of HSP in younger generations of a family is commonly observed based on awareness of the disease by other family members and treating physicians.</p></div><div id="spg3a.Nomenclature"><h3>Nomenclature</h3><p>"Silver syndrome <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>" refers to the inherited findings of spasticity and axonal motor neuropathy and/or distal amyotrophy [<a class="bk_pop" href="#spg3a.REF.silver.1966.69">Silver 1966</a>]. It is now known that these findings can be seen in a number of hereditary neurologic disorders caused by pathogenic variants in different genes (e.g., SPG3A caused by pathogenic variants in <i>ATL1</i> and <a href="/books/n/gene/spg17/"><i>BSCL2</i>-related neurologic disorders</a> caused by pathogenic variants in <i>BSCL2</i>) [<a class="bk_pop" href="#spg3a.REF.windpassinger.2004.271">Windpassinger et al 2004</a>].</p></div><div id="spg3a.Prevalence"><h3>Prevalence</h3><p>Estimated prevalence of AD HSP varies from 1.27:100,000 in the survey in Ireland to 12.4:100,000 based on a Norwegian epidemiologic study [<a class="bk_pop" href="#spg3a.REF.skre.1974.165">Skre 1974</a>, <a class="bk_pop" href="#spg3a.REF.mcmonagle.2002.43">McMonagle et al 2002</a>].</p><p><i>ATL1</i> pathogenic variants have been confirmed as the most common cause of early-onset HSP, accounting for approximately 30%-50% of all AD HSP with onset before age ten years [<a class="bk_pop" href="#spg3a.REF.abel.2004.239">Abel et al 2004</a>, <a class="bk_pop" href="#spg3a.REF.d_rr.2004.1867">D&#x000fc;rr et al 2004</a>].</p><p>SPG3A accounts for approximately 10%-15% of all AD HSP cases [<a class="bk_pop" href="#spg3a.REF.fink.1996.1507">Fink et al 1996</a>]. In an analysis of a large cohort of patients in whom a <i>SPAST</i> (formerly known as <i>SPG4</i>) <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> was not identified, 40% had pathogenic variants in <i>ATL1</i> [<a class="bk_pop" href="#spg3a.REF.d_rr.2004.1867">D&#x000fc;rr et al 2004</a>].</p></div></div><div id="spg3a.Genetically_Related_Allelic_Disord"><h2 id="_spg3a_Genetically_Related_Allelic_Disord_">Genetically Related (Allelic) Disorders</h2><p>SPG3A is allelic with hereditary sensory neuropathy type ID (HSN ID), which is an axonal form of <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> hereditary motor and sensory neuropathy distinguished by prominent sensory loss that leads to painless injuries. A pathogenic <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variant in <i>ATL1</i> was identified in a single family with HSN I; other known HSN I-associated genes were excluded as the cause of polyneuropathy [<a class="bk_pop" href="#spg3a.REF.guelly.2011.99">Guelly et al 2011</a>, <a class="bk_pop" href="#spg3a.REF.leonardis.2012.992">Leonardis et al 2012</a>].</p><p>Clinical presentation with a pure autonomic failure followed by the development of spastic paraplegia has also been reported in one individual with a novel pathogenic <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variant in <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 2 of <i>ATL1</i> [<a class="bk_pop" href="#spg3a.REF.shin.2014.141">Shin et al 2014</a>]. Whether this represents an allelic condition or an atypical presentation of SPG3A remains to be elucidated.</p></div><div id="spg3a.Differential_Diagnosis"><h2 id="_spg3a_Differential_Diagnosis_">Differential Diagnosis</h2><p>HSP is a progressive condition with a gradual worsening of spasticity and weakness of the lower extremities. Overall, the age of onset, disease severity, and rate of progression differ among different types of AD HSP; there is also considerable variability within the same genetic forms of HSP.</p><p>For a general discussion of the differential diagnosis of spastic paraplegia/paraparesis syndrome, see <a href="/books/n/gene/hsp/">Hereditary Spastic Paraplegia Overview</a>.</p><p>While the association of infantile or early (age &#x0003c;10 years) onset and pathogenic variants in <i>ATL1</i> has been confirmed by many studies, this <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a>-<a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> correlation is not sufficient for the specific diagnosis of SPG3A on clinical grounds alone as an early age of onset can be seen in other types of AD HSP. Overall, a low specificity of genotype/phenotype correlations in AD HSP requires the molecular diagnosis of a specific type of HSP.</p><p>SPG3A needs to be differentiated from other forms of AD HSP, such as <a href="/books/n/gene/spg17/"><i>BSCL2</i>-related neurologic disorders</a>, in which the Silver syndrome <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> can be observed. [<a class="bk_pop" href="#spg3a.REF.salameh.2009.57">Salameh et al 2009</a>].</p><p>SPG3A needs to be differentiated from other forms of AD HSP with possible early age of onset.</p><p>Additional considerations for SPG3A include a diplegic form of cerebral palsy (CP), as the majority of such patients tend to have very early onset of symptoms and a slow progression, which may suggest a static clinical course [<a class="bk_pop" href="#spg3a.REF.rainier.2006.445">Rainier et al 2006</a>]. The presence of a positive family history with an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> parent typically does not present any diagnostic dilemmas. However, incomplete <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> or a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> may lead to the diagnosis of diplegia caused by periventricular leukomalacia or perinatal hypoxic-ischemic injury. Normal pre- and perinatal history and unremarkable neuroimaging should prompt consideration of HSP, including SPG3A.</p><p><a href="/books/n/gene/spg4/">SPG4</a>, caused by pathogenic variants in <i>SPAST</i> (encoding spastin) is the most common type of AD HSP; it may occasionally present in infancy, although it tends to have a more progressive course [<a class="bk_pop" href="#spg3a.REF.blair.2007.382">Blair et al 2007</a>].</p><p>SPG6 (OMIM <a href="http://omim.org/entry/600636" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">600363</a>), caused by pathogenic variants in <i>NIPA1</i> (encoding magnesium transporter NIPA1), may occasionally also manifest in infancy [<a class="bk_pop" href="#spg3a.REF.bienwillner.2006.974">Bien-Willner et al 2006</a>]. This is probably the most aggressive form of AD HSP, leading to wheelchair dependency in a relatively short period of time.</p><p>SPG10 (OMIM <a href="http://omim.org/entry/604187" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">604187</a>), caused by pathogenic variants in <i>KIF5A</i> (encoding kinesin 5A), is probably the second most common cause of early-onset AD HSP. Axonal motor neuropathy is common [<a class="bk_pop" href="#spg3a.REF.reid.2002.1189">Reid et al 2002</a>].</p><p>SPG42 (OMIM <a href="http://omim.org/entry/612539" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">612539</a>), caused by pathogenic variants in <i>SLC33A1</i> (encoding acetyl-coenzyme A transporter 1), may also start in the first decade of life and has a mild, minimally progressive clinical course. Pes cavus and distal amyotrophy are common [<a class="bk_pop" href="#spg3a.REF.lin.2008.752">Lin et al 2008</a>]. This form of HSP has been reported in a single family.</p></div><div id="spg3a.Management"><h2 id="_spg3a_Management_">Management</h2><div id="spg3a.Evaluations_Following_Initial_Diag"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs in an individual diagnosed with spastic paraplegia 3A (SPG3A), the following evaluations may be indicated:</p><ul><li class="half_rhythm"><div>Orthopedic evaluation in persons with early onset of SPG3A who have developed musculoskeletal complications including scoliosis or foot deformities</div></li><li class="half_rhythm"><div>Physical and occupational therapy evaluation in children with early onset of disease</div></li><li class="half_rhythm"><div>Urologic evaluation in persons with prominent urinary bladder hyperactivity</div></li><li class="half_rhythm"><div>Electromyography and nerve conduction studies in persons with associated axonal neuropathy or neurogenic pain in the lower extremities caused by possible lumbo-sacral radiculopathy secondary to lumbar hyperlordosis and degenerative vertebral changes</div></li><li class="half_rhythm"><div>Consultation with a clinical geneticist and/or genetic counselor</div></li></ul></div><div id="spg3a.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p>Therapy for spasticity, distal weakness, and urinary bladder dysfunction, the primary manifestations of SPG3A, is symptomatic.</p><p><b>Spasticity</b> can be treated with:</p><ul><li class="half_rhythm"><div>Oral baclofen or tizanidine</div></li><li class="half_rhythm"><div>Chemodenervation with botulinum A or B toxins; may be tried in those who do not tolerate oral antispasticity medications</div></li><li class="half_rhythm"><div>Intrathecal baclofen pump; a good alternative for patients who improve on oral baclofen but cannot tolerate a therapeutic dose because of systemic adverse effects</div></li></ul><p>Each of the above therapies should be combined with intensive physical therapy focused on stretching and strengthening exercises.</p><p>The role of surgical therapy for spasticity (including hamstring and heel cord lengthening and release of the adductor longus) remains unknown, but such treatment should be considered if contractures appear. See also <a href="#spg3a.Prevention_of_Secondary_Complicati">Prevention of Secondary Complications</a>.</p><p><b>Distal weakness</b>, typically affecting foot dorsiflexion, can be ameliorated by ankle-foot orthoses; referral to orthotic services may be helpful.</p><p><b>Urinary urgency</b> can be treated with anticholinergic antispasmodic drugs.</p></div><div id="spg3a.Prevention_of_Secondary_Complicati"><h3>Prevention of Secondary Complications</h3><p>Musculoskeletal abnormalities including muscle tendon contractures, scoliosis, and foot deformities are the secondary complications most likely to occur, resulting from long-standing spasticity and weakness. Intense and regular therapy for spasticity, including physiotherapy, can delay and minimize the appearance of these complications. The higher incidence of orthopedic problems in patients with SPG3A may be related to early age of onset and these patients should be followed by an orthopedist if problems are present.</p><p>Urinary bladder incontinence can be a secondary complication of a neurogenic bladder and urologic care may be needed.</p><p>Patients with advanced disease may experience falls with a risk of traumatic injury. A walking aid (cane, walker, or wheelchair) may need to be considered in patients experiencing falls.</p></div><div id="spg3a.Surveillance"><h3>Surveillance</h3><p>There is no consensus regarding the frequency of clinical follow-up visits, but every person with HSP should be reevaluated once or twice a year to identify new complications early and to initiate aggressive therapy as indicated.</p></div><div id="spg3a.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p>Dantrolene should be avoided in persons who are ambulatory as it may induce irreversible weakness, which can adversely interfere with overall mobility.</p></div><div id="spg3a.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>See <a href="#spg3a.Related_Genetic_Counseling_Issues">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="spg3a.Pregnancy_Management"><h3>Pregnancy Management</h3><p>The use of regional anesthesia, such as spinal or epidural anesthesia, during delivery in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> women with spinal cord involvement has traditionally been avoided due to the theoretic risk of exacerbating the degree of weakness and spasticity. However, several cases of successful regional anesthesia in affected individuals with hereditary spastic paraplegia have been reported [<a class="bk_pop" href="#spg3a.REF.thomas.2006.254">Thomas et al 2006</a>].</p></div><div id="spg3a.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>Search <a href="https://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.ClinicalTrialsRegister.eu" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.ClinicalTrialsRegister.eu</a> in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p></div></div><div id="spg3a.Genetic_Counseling"><h2 id="_spg3a_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="spg3a.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>Spastic paraplegia 3A (SPG3A) is typically inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner.</p><p>Recently, a family with SPG3A with presumed <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> inheritance was reported by <a class="bk_pop" href="#spg3a.REF.khan.2014.1180">Khan et al [2014]</a>. Such inheritance is extremely rare and as yet unconfirmed.</p></div><div id="spg3a.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>Most individuals (&#x0003e;95%) diagnosed with spastic paraplegia 3A have an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> parent.</div></li><li class="half_rhythm"><div>A <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with SPG 3A may have the disorder as the result of a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>. The proportion of cases caused by <i>de novo</i> pathogenic variants is currently unknown.</div></li><li class="half_rhythm"><div>If the <i>ATL1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> found in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> cannot be detected in leukocyte DNA of either parent, two possible explanations are <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a> in a parent or a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> pathogenic variant in the proband. Although no instances of germline mosaicism have been reported, it remains a possibility.</div></li><li class="half_rhythm"><div>Recommendations for the evaluation of parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with an apparent <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> include a comprehensive neurologic examination.</div></li><li class="half_rhythm"><div>The family history of some individuals diagnosed with SPG3A may appear to be negative because of failure to recognize the disorder in family members, early death of the parent before the onset of symptoms, or late onset of the disease in the <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> parent. Therefore, an apparently negative family history cannot be confirmed unless appropriate <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> has been performed on the parents of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</div></li></ul><p>Note: If the parent is the individual in whom the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> first occurred, s/he may have <a class="def" href="/books/n/gene/glossary/def-item/somatic-mosaicism/">somatic mosaicism</a> for the pathogenic variant and may be mildly/minimally <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>.</p><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The risk to the sibs of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> depends on the genetic status of the proband's parents.</div></li><li class="half_rhythm"><div>If a parent of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> is <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> and/or has an <i>ATL1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, the risk to the sibs of inheriting the variant is 50%.</div></li><li class="half_rhythm"><div>When the parents are clinically unaffected, the risk to the sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> appears to be low (&#x0003c; 5%).</div></li><li class="half_rhythm"><div>The sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with clinically unaffected parents are still at increased risk for spastic paraplegia 3A because of the possibility of reduced <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> in a parent.</div></li><li class="half_rhythm"><div>If the <i>ATL1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> found in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> cannot be detected in the leukocyte DNA of either parent, the risk to sibs is low, but greater than that of the general population because of the possibility of <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a>.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> Each child of an individual with spastic paraplegia 3A has a 50% chance of inheriting the <i>ATL1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p><p><b>Other family members</b></p><ul><li class="half_rhythm"><div>The risk to other family members depends on the status of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s parents.</div></li><li class="half_rhythm"><div>If a parent is <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> or has an <i>ATL1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, his or her family members may be at risk.</div></li></ul></div><div id="spg3a.Related_Genetic_Counseling_Issues"><h3>Related Genetic Counseling Issues</h3><p><b>Testing of at-risk asymptomatic adult relatives</b> of individuals with SPG3A is possible after <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> has identified the specific <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the family. Such testing should be performed in the context of formal <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> and is not useful in predicting age of onset, severity, type of symptoms, or rate of progression in asymptomatic individuals. Testing of asymptomatic at-risk individuals with nonspecific or equivocal symptoms is predictive testing, not diagnostic testing.</p><p><b>Testing of asymptomatic individuals younger than age 18 years</b> who are at risk for adult-onset disorders for which no treatment exists is not considered appropriate, primarily because it negates the autonomy of the child with no compelling benefit. Further, concern exists regarding the potential unhealthy adverse effects that such information may have on family dynamics, the risk of discrimination and stigmatization in the future, and the anxiety that such information may cause.</p><p>Testing is appropriate to consider in symptomatic individuals in a family with an established diagnosis of SPG3A regardless of age.</p><p>See also the National Society of Genetic Counselors <a href="http://www.nsgc.org/p/bl/et/blogaid=860" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">position statement</a> on genetic testing of minors for adult-onset conditions and the American Academy of Pediatrics and American College of Medical Genetics and Genomics <a href="http://pediatrics.aappublications.org/content/131/3/620.full.pdf" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">policy statement</a>: ethical and policy issues in genetic testing and screening of children.</p><p><b>Considerations in families with an apparent <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</b> When neither parent of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with SPG3A has the <i>ATL1</i> pathogenic variant, the <i>ATL1</i> variant is likely <i>de novo</i>. However, possible non-medical explanations including <a class="def" href="/books/n/gene/glossary/def-item/alternate-paternity/">alternate paternity</a> or maternity (e.g., with assisted reproduction) or undisclosed adoption could also be explored.</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> or at risk.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="spg3a.Prenatal_Testing_and_Preimplantati"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p>Once the <i>ATL1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> for SPGA are possible.</p><p>Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. While decisions regarding prenatal testing are the choice of the parents, discussion of these issues is appropriate.</p></div></div><div id="spg3a.Resources"><h2 id="_spg3a_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>HSP Research Foundation</b></div><div>P.O. Box 4064</div><div>Warrimoo New South Wales NSW 2774</div><div>Australia</div><div><a href="https://www.hspersunite.org.au/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.hspersunite.org.au</a></div></li><li class="half_rhythm"><div><b>National Institute of Neurological Disorders and Stroke (NINDS)</b></div><div>PO Box 5801</div><div>Bethesda MD 20824</div><div><b>Phone:</b> 800-352-9424 (toll-free); 301-496-5751; 301-468-5981 (TTY)</div><div><a href="https://www.ninds.nih.gov/Disorders/All-Disorders/Hereditary-Spastic-Paraplegia-Information-Page" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Hereditary Spastic Paraplegia Information Page</a></div></li><li class="half_rhythm"><div><b>Spastic Paraplegia Foundation, Inc.</b></div><div>7700 Leesburg Pike</div><div>Ste 123</div><div>Falls Church VA 22043</div><div><b>Phone:</b> 877-773-4483 (toll-free)</div><div><b>Email:</b> information@sp-foundation.org</div><div><a href="http://sp-foundation.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">sp-foundation.org</a></div></li></ul></div><div id="spg3a.Molecular_Genetics"><h2 id="_spg3a_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="spg3a.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>Spastic Paraplegia 3A: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK45978/table/spg3a.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__spg3a.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_spg3a.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Locus Name</th><th id="hd_b_spg3a.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_spg3a.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_spg3a.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_spg3a.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_spg3a.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_spg3a.molgen.TA_1_1_1_7" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_spg3a.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">SPG3A</td><td headers="hd_b_spg3a.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/51062" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>ATL1</i></a></td><td headers="hd_b_spg3a.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=51062" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">14q22<wbr style="display:inline-block"></wbr>​.1</a></td><td headers="hd_b_spg3a.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/Q8WXF7" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Atlastin-1</a></td><td headers="hd_b_spg3a.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://reseq.biosciencedbc.jp/resequence/GeneDetail.do?targetId=9&#x00026;geneId=EG51062" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HSP mutation database (ATL1)</a><br /><a href="https://databases.lovd.nl/shared/genes/ATL1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ATL1 homepage - Leiden Muscular Dystrophy pages</a></td><td headers="hd_b_spg3a.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=ATL1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ATL1</a></td><td headers="hd_b_spg3a.molgen.TA_1_1_1_7" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=ATL1[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ATL1</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="spg3a.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="spg3a.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for Spastic Paraplegia 3A (<a href="/omim/182600,606439" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK45978/table/spg3a.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__spg3a.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/182600" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">182600</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">SPASTIC PARAPLEGIA 3, AUTOSOMAL DOMINANT; SPG3A</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/606439" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">606439</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">ATLASTIN GTPase 1; ATL1</td></tr></tbody></table></div></div><p><b>Gene structure.</b>
<i>ATL1</i> is 73 kb in length and spans from nucleotide position 51,026,743 to 51,099,782. Transcript variants encoding two different <a class="def" href="/books/n/gene/glossary/def-item/isoforms/">isoforms</a> with 13 or 14 transcribed exons have been found for this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>. Complementary DNA length varies from 2,74 bp to 2,812 bp for different variants. For a detailed summary of gene and protein information, see <a href="/books/NBK45978/#spg3a.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Benign variants.</b> Both synonymous and nonsynonymous single polymorphisms (benign variants) have been identified (see <a class="figpopup" href="/books/NBK45978/table/spg3a.T.selected_atl1_benign_variants/?report=objectonly" target="object" rid-figpopup="figspg3aTselectedatl1benignvariants" rid-ob="figobspg3aTselectedatl1benignvariants">Table 2</a>).</p><div id="spg3a.T.selected_atl1_benign_variants" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Selected <i>ATL1</i> Benign Variants</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK45978/table/spg3a.T.selected_atl1_benign_variants/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__spg3a.T.selected_atl1_benign_variants_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_spg3a.T.selected_atl1_benign_variants_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change</th><th id="hd_h_spg3a.T.selected_atl1_benign_variants_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference SNP Number</th><th id="hd_h_spg3a.T.selected_atl1_benign_variants_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_spg3a.T.selected_atl1_benign_variants_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_spg3a.T.selected_atl1_benign_variants_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.84A&#x0003e;G</td><td headers="hd_h_spg3a.T.selected_atl1_benign_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="/projects/SNP/snp_ref.cgi?rs=35014209" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">rs35014209</a></td><td headers="hd_h_spg3a.T.selected_atl1_benign_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">NA</td><td headers="hd_h_spg3a.T.selected_atl1_benign_variants_1_1_1_4" rowspan="6" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/nuccore/213972601" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NG_009028<wbr style="display:inline-block"></wbr>​.1</a><br /><a href="/nuccore/189181739" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_015915<wbr style="display:inline-block"></wbr>​.4</a><br /><a href="/protein/NP_056999.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_056999<wbr style="display:inline-block"></wbr>​.2</a><br /><a href="/protein/115502838" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Q5R4P1<wbr style="display:inline-block"></wbr>​.2</a></td></tr><tr><td headers="hd_h_spg3a.T.selected_atl1_benign_variants_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.129C&#x0003e;G</td><td headers="hd_h_spg3a.T.selected_atl1_benign_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="/projects/SNP/snp_ref.cgi?rs=17850684" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">rs17850684</a></td><td headers="hd_h_spg3a.T.selected_atl1_benign_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Asp43Glu</td></tr><tr><td headers="hd_h_spg3a.T.selected_atl1_benign_variants_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.351G&#x0003e;A</td><td headers="hd_h_spg3a.T.selected_atl1_benign_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="/sites/snp" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">rs1060197</a></td><td headers="hd_h_spg3a.T.selected_atl1_benign_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">NA</td></tr><tr><td headers="hd_h_spg3a.T.selected_atl1_benign_variants_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.578T&#x0003e;G</td><td headers="hd_h_spg3a.T.selected_atl1_benign_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="/projects/SNP/snp_ref.cgi?rs=17850683" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">rs17850683</a></td><td headers="hd_h_spg3a.T.selected_atl1_benign_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Phe193Cys</td></tr><tr><td headers="hd_h_spg3a.T.selected_atl1_benign_variants_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.621G&#x0003e;A</td><td headers="hd_h_spg3a.T.selected_atl1_benign_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="/projects/SNP/snp_ref.cgi?rs=35629585" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">rs35629585</a></td><td headers="hd_h_spg3a.T.selected_atl1_benign_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">NA</td></tr><tr><td headers="hd_h_spg3a.T.selected_atl1_benign_variants_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1222A&#x0003e;G</td><td headers="hd_h_spg3a.T.selected_atl1_benign_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="/projects/SNP/snp_ref.cgi?rs=28939094" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">rs28939094</a></td><td headers="hd_h_spg3a.T.selected_atl1_benign_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Met408Val</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Note on variant classification: Variants listed in the table have been provided by the author. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin">Note on nomenclature: <i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd><dt></dt><dd><div><p class="no_margin">NA = not applicable</p></div></dd></dl></div></div></div><p><b>Pathogenic variants.</b> Most pathogenic variants in <i>ATL1</i> are unique and no obvious hot spots for recurrent variants have been identified [<a class="bk_pop" href="#spg3a.REF.d_rr.2004.1867">D&#x000fc;rr et al 2004</a>]. One <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> of <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 4 has been reported [<a class="bk_pop" href="#spg3a.REF.sulek.2013.239">Sulek et al 2013</a>].</p><div id="spg3a.T.selected_atl1_pathogenic_variant" class="table"><h3><span class="label">Table 3. </span></h3><div class="caption"><p>Selected <i>ATL1</i> Pathogenic Variants</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK45978/table/spg3a.T.selected_atl1_pathogenic_variant/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__spg3a.T.selected_atl1_pathogenic_variant_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_spg3a.T.selected_atl1_pathogenic_variant_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change<br />(Alias&#x000a0;<sup>1</sup>)</th><th id="hd_h_spg3a.T.selected_atl1_pathogenic_variant_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change<br />(Alias&#x000a0;<sup>1</sup>)</th><th id="hd_h_spg3a.T.selected_atl1_pathogenic_variant_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_spg3a.T.selected_atl1_pathogenic_variant_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1243C&#x0003e;T</td><td headers="hd_h_spg3a.T.selected_atl1_pathogenic_variant_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg415Trp&#x000a0;<sup>2</sup></td><td headers="hd_h_spg3a.T.selected_atl1_pathogenic_variant_1_1_1_3" rowspan="6" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/nuccore/189181739" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_015915<wbr style="display:inline-block"></wbr>​.3</a><br /><a href="/protein/NP_056999.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_056999<wbr style="display:inline-block"></wbr>​.2</a></td></tr><tr><td headers="hd_h_spg3a.T.selected_atl1_pathogenic_variant_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.467C&#x0003e;T<br />(635C&#x0003e;T)</td><td headers="hd_h_spg3a.T.selected_atl1_pathogenic_variant_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.The156Ile</td></tr><tr><td headers="hd_h_spg3a.T.selected_atl1_pathogenic_variant_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.715C&#x0003e;T<br />(884C&#x0003e;T)</td><td headers="hd_h_spg3a.T.selected_atl1_pathogenic_variant_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg239Cys</td></tr><tr><td headers="hd_h_spg3a.T.selected_atl1_pathogenic_variant_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.773A&#x0003e;G<br />(942A&#x0003e;C)</td><td headers="hd_h_spg3a.T.selected_atl1_pathogenic_variant_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.His258Arg</td></tr><tr><td headers="hd_h_spg3a.T.selected_atl1_pathogenic_variant_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.479T&#x0003e;G<br />(638T&#x0003e;C)</td><td headers="hd_h_spg3a.T.selected_atl1_pathogenic_variant_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Leu157Trp</td></tr><tr><td headers="hd_h_spg3a.T.selected_atl1_pathogenic_variant_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1270dupA<br />(1688insA)</td><td headers="hd_h_spg3a.T.selected_atl1_pathogenic_variant_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ile424AsnfsTer16<br />(522Stop)</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Note on variant classification: Variants listed in the table have been provided by the author. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin">Note on nomenclature: <i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd><dt>1. </dt><dd><div id="spg3a.TF.3.1"><p class="no_margin">Variant designation that does not conform to current naming conventions</p></div></dd><dt>2. </dt><dd><div id="spg3a.TF.3.2"><p class="no_margin">Low-<a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> (see <a href="#spg3a.Penetrance">Penetrance</a>)</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b>
<i>ATL1</i> encodes a 558-amino acid protein named atlastin-1 belonging to the subclass of GTPases called dynamins. Dynamins play a role in vesicle transport, especially in the process of recycling of the vesicles. The protein has two transmembrane domains and also contains the GTP binding <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> with a catalytic activity [<a class="bk_pop" href="#spg3a.REF.zhu.2003.49063">Zhu et al 2003</a>]. Atlastin-1 is predominantly expressed in the pyramidal neurons giving the origin to the pyramidal tracts, which undergo axonal degeneration in patients with HSP. It localizes predominantly to the endoplasmatic reticulum (ER) and Golgi complex but is also found in other subcellular compartments, including the axonal growth cones [<a class="bk_pop" href="#spg3a.REF.zhu.2003.49063">Zhu et al 2003</a>, <a class="bk_pop" href="#spg3a.REF.zhu.2006.1343">Zhu et al 2006</a>]. Atlastin-1 plays an important role in the formation of the tubular ER network, where it may coordinate the interaction between microtubules and the tubular ER network [<a class="bk_pop" href="#spg3a.REF.hu.2009.549">Hu et al 2009</a>, <a class="bk_pop" href="#spg3a.REF.park.2010.1097">Park et al 2010</a>]. Atlastin-1 also interacts with spastin, which causes the most common form of AD HSP and is known to function as a microtubule-severing protein [<a class="bk_pop" href="#spg3a.REF.sanderson.2006.307">Sanderson et al 2006</a>].</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Most disease-causing <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants in <i>ATL1</i> are clustered around the GTPase <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a>, resulting in reduction of catalytic activity. However, it is still not clear whether SPG3A results from a loss of atlastin-1 function: a <a class="def" href="/books/n/gene/glossary/def-item/dominant-negative/">dominant-negative</a> effect of mutated protein forms on a wild type of atlastin-1 has also been suggested. Atlastin-1 forms tetrameric complexes and heterocomplexes of wild type and mutated atlastin-1 molecules may inactivate the normal function of wild type atlastin-1, consistent with a dominant-negative effect [<a class="bk_pop" href="#spg3a.REF.zhu.2003.49063">Zhu et al 2003</a>]. Expression of pathogenic variants of atlastin-1 results in abnormal connectivity of ER complex and these ER-shaping defects may represent a novel neuropathogenic mechanism [<a class="bk_pop" href="#spg3a.REF.hu.2009.549">Hu et al 2009</a>]. Additionally, atlastin-1 appears to be enriched in neuronal growth cones, and knockdown of atlastin-1 expression was found to impair axonal elongation [<a class="bk_pop" href="#spg3a.REF.zhu.2006.1343">Zhu et al 2006</a>].</p></div><div id="spg3a.References"><h2 id="_spg3a_References_">References</h2><div id="spg3a.Published_Guidelines__Consensus_St"><h3>Published Guidelines / Consensus Statements</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="spg3a.REF1">Committee on Bioethics, Committee on Genetics, and American College of Medical Genetics and Genomics Social, Ethical, Legal Issues Committee. Ethical and policy issues in genetic testing and screening of children. Available <a href="http://pediatrics.aappublications.org/content/131/3/620.full.pdf" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 2013. Accessed 11-5-18. [<a href="/pubmed/23428972" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23428972</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="spg3a.REF2">National Society of Genetic Counselors. Position statement on genetic testing of minors for adult-onset disorders. Available <a href="http://www.nsgc.org/p/bl/et/blogaid=860" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 2017. Accessed 11-5-18.</div></li></ul></div><div id="spg3a.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="spg3a.REF.abel.2004.239">Abel A, Fonknechten N, Hofer A, D&#x000fc;rr A, Cruaud C, Voit T, Weissenbach J, Brice A, Klimpe S, Auburger G, Hazan J. Early onset autosomal dominant spastic paraplegia caused by novel mutations in SPG3A. <span><span class="ref-journal">Neurogenetics. </span>2004;<span class="ref-vol">5</span>:239–43.</span> [<a href="/pubmed/15517445" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15517445</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="spg3a.REF.bienwillner.2006.974">Bien-Willner R, Sambuughin N, Holley H, Bodensteiner J, Sivakumar K. Childhood-onset spastic paraplegia with NIPA1 gene mutation. <span><span class="ref-journal">J Child Neurol. </span>2006;<span class="ref-vol">21</span>:974–7.</span> [<a href="/pubmed/17092466" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17092466</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="spg3a.REF.blair.2007.382">Blair MA, Riddle ME, Wells JF, Breviu BA, Hedera P. Infantile onset of hereditary spastic paraplegia poorly predicts the genotype. <span><span class="ref-journal">Pediatr Neurol. </span>2007;<span class="ref-vol">36</span>:382–6.</span> [<a href="/pubmed/17560499" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17560499</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="spg3a.REF.damico.2004.2138">D'Amico A, Tessa A, Sabino A, Bertini E, Santorelli FM, Servidei S. Incomplete penetrance in an SPG3A-linked family with a new mutation in the atlastin gene. <span><span class="ref-journal">Neurology. </span>2004;<span class="ref-vol">62</span>:2138–9.</span> [<a href="/pubmed/15184642" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15184642</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="spg3a.REF.d_rr.2004.1867">D&#x000fc;rr A, Camuzat A, Colin E, Tallaksen C, Hannequin D, Coutinho P, Fontaine B, Rossi A, Gil R, Rousselle C, Ruberg M, Stevanin G, Brice A. Atlastin1 mutations are frequent in young-onset autosomal dominant spastic paraplegia. <span><span class="ref-journal">Arch Neurol. </span>2004;<span class="ref-vol">61</span>:1867–72.</span> [<a href="/pubmed/15596607" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15596607</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="spg3a.REF.fink.1996.1507">Fink JK, Heiman-Patterson T, Bird T, Cambi F, Dub&#x000e9; MP, Figlewicz DA, Haines JL, Hentati A, Pericak-Vance MA, Raskind W, Rouleau GA, Siddique T. Hereditary spastic paraplegia: advances in genetic research. <span><span class="ref-journal">Neurology. </span>1996;<span class="ref-vol">46</span>:1507–14.</span> [<a href="/pubmed/8649538" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8649538</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="spg3a.REF.guelly.2011.99">Guelly C, Zhu PP, Leonardis L, Papi&#x00107; L, Zidar J, Schabh&#x000fc;ttl M, Strohmaier H, Weis J, Strom TM, Baets J, Willems J, De Jonghe P, Reilly MM, Fr&#x000f6;hlich E, Hatz M, Trajanoski S, Pieber TR, Janecke AR, Blackstone C, Auer-Grumbach M. Targeted high-throughput sequencing identifies mutations in atlastin-1 as a cause of hereditary sensory neuropathy type I. <span><span class="ref-journal">Am J Hum Genet. </span>2011;<span class="ref-vol">88</span>:99–105.</span> [<a href="/pmc/articles/PMC3014370/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3014370</span></a>] [<a href="/pubmed/21194679" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21194679</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="spg3a.REF.hedera.2004.1600">Hedera P, Fenichel GM, Blair M, Haines JL. Novel mutation in the SPG3A gene in an African American family with an early onset of hereditary spastic paraplegia. <span><span class="ref-journal">Arch Neurol. </span>2004;<span class="ref-vol">61</span>:1600–3.</span> [<a href="/pubmed/15477516" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15477516</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="spg3a.REF.hu.2009.549">Hu J, Shibata Y, Zhu PP, Voss C, Rismanchi N, Prinz WA, Rapoport TA, Blackstone C. A class of dynamin-like GTPases involved in the generation of the tubular ER network. <span><span class="ref-journal">Cell. </span>2009;<span class="ref-vol">138</span>:549–61.</span> [<a href="/pmc/articles/PMC2746359/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2746359</span></a>] [<a href="/pubmed/19665976" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19665976</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="spg3a.REF.ivanova.2007.706">Ivanova N, Claeys KG, Deconinck T, Litvinenko I, Jordanova A, Auer-Grumbach M, Haberlova J, L&#x000f6;fgren A, Smeyers G, Nelis E, Mercelis R, Plecko B, Priller J, Z&#x000e1;mecn&#x000ed;k J, Ceulemans B, Erichsen AK, Bj&#x000f6;rck E, Nicholson G, Sereda MW, Seeman P, Kremensky I, Mitev V, De Jonghe P. Hereditary spastic paraplegia 3A associated with axonal neuropathy. <span><span class="ref-journal">Arch Neurol. </span>2007;<span class="ref-vol">64</span>:706–13.</span> [<a href="/pubmed/17502470" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17502470</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="spg3a.REF.khan.2014.1180">Khan TN, Klar J, Tariq M, Anjum Baig S, Malik NA, Yousaf R, Baig SM, Dahl N. Evidence for autosomal recessive inheritance in SPG3A caused by homozygosity for a novel ATL1 missense mutation. <span><span class="ref-journal">Eur J Hum Genet. </span>2014;<span class="ref-vol">22</span>:1180–4.</span> [<a href="/pmc/articles/PMC4169543/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4169543</span></a>] [<a href="/pubmed/24473461" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24473461</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="spg3a.REF.leonardis.2012.992">Leonardis L, Auer-Grumbach M, Papi&#x00107; L, Zidar J. The N355K atlastin 1 mutation is associated with hereditary sensory neuropathy and pyramidal tract features. <span><span class="ref-journal">Eur J Neurol. </span>2012;<span class="ref-vol">19</span>:992–8.</span> [<a href="/pubmed/22340599" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22340599</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="spg3a.REF.lin.2008.752">Lin P, Li J, Liu Q, Mao F, Li J, Qiu R, Hu H, Song Y, Yang Y, Gao G, Yan C, Yang W, Shao C, Gong Y. A missense mutation in SLC33A1, which encodes the acetyl-CoA transporter, causes autosomal-dominant spastic paraplegia (SPG42). <span><span class="ref-journal">Am J Hum Genet. </span>2008;<span class="ref-vol">83</span>:752–9.</span> [<a href="/pmc/articles/PMC2668077/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2668077</span></a>] [<a href="/pubmed/19061983" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19061983</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="spg3a.REF.mcmonagle.2002.43">McMonagle P, Webb S, Hutchinson M. The prevalence of "pure" autosomal dominant hereditary spastic paraparesis in the island of Ireland. <span><span class="ref-journal">J Neurol Neurosurg Psychiatry. </span>2002;<span class="ref-vol">72</span>:43–6.</span> [<a href="/pmc/articles/PMC1737699/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1737699</span></a>] [<a href="/pubmed/11784824" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11784824</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="spg3a.REF.park.2010.1097">Park SH, Zhu PP, Parker RL, Blackstone C. Hereditary spastic paraplegia proteins REEP1, spastin, and atlastin-1 coordinate microtubule interactions with the tubular ER network. <span><span class="ref-journal">J Clin Invest. </span>2010;<span class="ref-vol">120</span>:1097–110.</span> [<a href="/pmc/articles/PMC2846052/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2846052</span></a>] [<a href="/pubmed/20200447" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20200447</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="spg3a.REF.rainier.2006.445">Rainier S, Sher C, Reish O, Thomas D, Fink JK. De novo occurrence of novel SPG3A/atlastin mutation presenting as cerebral palsy. <span><span class="ref-journal">Arch Neurol. </span>2006;<span class="ref-vol">63</span>:445–7.</span> [<a href="/pubmed/16533974" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16533974</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="spg3a.REF.reid.2002.1189">Reid E, Kloos M, Ashley-Koch A, Hughes L, Bevan S, Svenson IK, Graham FL, Gaskell PC, Dearlove A, Pericak-Vance MA, Rubinsztein DC, Marchuk DA. A kinesin heavy chain (KIF5A) mutation in hereditary spastic paraplegia (SPG10). <span><span class="ref-journal">Am J Hum Genet. </span>2002;<span class="ref-vol">71</span>:1189–94.</span> [<a href="/pmc/articles/PMC385095/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC385095</span></a>] [<a href="/pubmed/12355402" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12355402</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="spg3a.REF.salameh.2009.57">Salameh JS, Shenoy AM, David WS. Novel SPG3A and SPG4 mutations in two patients with Silver syndrome. <span><span class="ref-journal">J Clin Neuromuscul Dis. </span>2009;<span class="ref-vol">11</span>:57–59.</span> [<a href="/pubmed/19730024" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19730024</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="spg3a.REF.sanderson.2006.307">Sanderson CM, Connell JW, Edwards TL, Bright NA, Duley S, Thompson A, Luzio JP, Reid E. Spastin and atlastin, two proteins mutated in autosomal-dominant hereditary spastic paraplegia, are binding partners. <span><span class="ref-journal">Hum Mol Genet. </span>2006;<span class="ref-vol">15</span>:307–18.</span> [<a href="/pmc/articles/PMC2443951/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2443951</span></a>] [<a href="/pubmed/16339213" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16339213</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="spg3a.REF.sauter.2004.98">Sauter SM, Engel W, Neumann LM, Kunze J, Neesen J. Novel mutations in the Atlastin gene (SPG3A) in families with autosomal dominant hereditary spastic paraplegia and evidence for late onset forms of HSP linked to the SPG3A locus. <span><span class="ref-journal">Hum Mutat. </span>2004;<span class="ref-vol">23</span>:98.</span> [<a href="/pubmed/14695538" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14695538</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="spg3a.REF.scarano.2005.901">Scarano V, Mancini P, Criscuolo C, De Michele G, Rinaldi C, Tucci T, Tessa A, Santorelli FM, Perretti A, Santoro L, Filla A. The R495W mutation in SPG3A causes spastic paraplegia associated with axonal neuropathy. <span><span class="ref-journal">J Neurol. </span>2005;<span class="ref-vol">252</span>:901–3.</span> [<a href="/pubmed/15742100" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15742100</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="spg3a.REF.shin.2014.141">Shin JW, Jung KH, Lee ST, Moon J, Seong MW, Park SS, Lee SK, Chu K. Novel mutation in the ATL1 with autosomal dominant hereditary spastic paraplegia presented as dysautonomia. <span><span class="ref-journal">Auton Neurosci. </span>2014;<span class="ref-vol">185</span>:141–3.</span> [<a href="/pubmed/24969372" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24969372</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="spg3a.REF.silver.1966.69">Silver JR. Familial spastic paraplegia with amyotrophy of the hands. <span><span class="ref-journal">Ann Hum Genet. </span>1966;<span class="ref-vol">30</span>:69–75.</span> [<a href="/pubmed/5964029" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 5964029</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="spg3a.REF.skre.1974.165">Skre H. Hereditary spastic paraplegia in Western Norway. <span><span class="ref-journal">Clin Genet. </span>1974;<span class="ref-vol">6</span>:165–83.</span> [<a href="/pubmed/4426134" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 4426134</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="spg3a.REF.sulek.2013.239">Sulek A, Elert E, Rajkiewicz M, Zdzienicka E, Stepniak I, Krysa W, Zaremba J. Screening for the hereditary spastic paraplaegias SPG4 and SPG3A with the multiplex ligation-dependent probe amplification technique in a large population of affected individuals. <span><span class="ref-journal">Neurol Sci. </span>2013;<span class="ref-vol">34</span>:239–42.</span> [<a href="/pubmed/22203332" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22203332</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="spg3a.REF.tessa.2002.2002">Tessa A, Casali C, Damiano M, Bruno C, Fortini D, Patrono C, Cricchi F, Valoppi M, Nappi G, Amabile GA, Bertini E, Santorelli FM. SPG3A: An additional family carrying a new atlastin mutation. <span><span class="ref-journal">Neurology. </span>2002;<span class="ref-vol">59</span>:2002–5.</span> [<a href="/pubmed/12499504" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12499504</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="spg3a.REF.thomas.2006.254">Thomas I, Thomas M, Scrutton M. Spinal anaesthesia in a patient with hereditary spastic paraplegia: case report and literature review. <span><span class="ref-journal">Int J Obstet Anesth. </span>2006;<span class="ref-vol">15</span>:254–6.</span> [<a href="/pubmed/16798455" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16798455</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="spg3a.REF.windpassinger.2004.271">Windpassinger C, Auer-Grumbach M, Irobi J, Patel H, Petek E, H&#x000f6;rl G, Malli R, Reed JA, Dierick I, Verpoorten N, Warner TT, Proukakis C, Van den Bergh P, Verellen C, Van Maldergem L, Merlini L, De Jonghe P, Timmerman V, Crosby AH, Wagner K. Heterozygous missense mutations in BSCL2 are associated with distal hereditary motor neuropathy and Silver syndrome. <span><span class="ref-journal">Nat Genet. </span>2004;<span class="ref-vol">36</span>:271–6.</span> [<a href="/pubmed/14981520" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14981520</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="spg3a.REF.zhao.2001.326">Zhao X, Alvarado D, Rainier S, Lemons R, Hedera P, Weber CH, Tukel T, Apak M, Heiman-Patterson T, Ming L, Bui M, Fink JK. Mutations in a novel GTPase cause autosomal dominant hereditary spastic paraplegia. <span><span class="ref-journal">Nat Genet. </span>2001;<span class="ref-vol">29</span>:326–31.</span> [<a href="/pubmed/11685207" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11685207</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="spg3a.REF.zhu.2003.49063">Zhu PP, Patterson A, Lavoie B, Stadler J, Shoeb M, Patel R, Blackstone C. Cellular localization, oligomerization, and membrane association of the hereditary spastic paraplegia 3A (SPG3A) protein atlastin. <span><span class="ref-journal">J Biol Chem. </span>2003;<span class="ref-vol">278</span>:49063–71.</span> [<a href="/pubmed/14506257" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14506257</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="spg3a.REF.zhu.2006.1343">Zhu PP, Soderblom C, Tao-Cheng JH, Stadler J, Blackstone C. SPG3A protein atlastin-1 is enriched in growth cones and promotes axon elongation during neuronal development. <span><span class="ref-journal">Hum Mol Genet. </span>2006;<span class="ref-vol">15</span>:1343–53.</span> [<a href="/pubmed/16537571" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16537571</span></a>]</div></li></ul></div></div><div id="spg3a.Chapter_Notes"><h2 id="_spg3a_Chapter_Notes_">Chapter Notes</h2><div id="spg3a.Author_Notes"><h3>Author Notes</h3><p>Author's <a href="http://www.mc.vanderbilt.edu/root/vumc.php?site=neurology&#x00026;doc=26232" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">web page</a></p></div><div id="spg3a.Acknowledgments"><h3>Acknowledgments</h3><p>P Hedera is supported by NIH (NINDS) grant K02NS057666</p></div><div id="spg3a.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>11 December 2014 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>9 February 2012 (cd) Revision: single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> in <i>ATL1</i> found to cause SPG3A [<a class="bk_pop" href="#spg3a.REF.sulek.2013.239">Sulek et al 2013</a>]; HSN ID identified as allelic disorder</div></li><li class="half_rhythm"><div>21 September 2010 (me) Review posted live</div></li><li class="half_rhythm"><div>26 April 2010 (ph) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK45978</span><span class="label">PMID: <a href="/pubmed/20862796" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20862796</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/sotos/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/spg4/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK45978&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK45978/?report=reader">PubReader</a></li><li><a href="/books/NBK45978/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK45978" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK45978" style="display:none" title="Cite this Page"><div class="bk_tt">Hedera P. Spastic Paraplegia 3A. 2010 Sep 21 [Updated 2014 Dec 11]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK45978/pdf/Bookshelf_NBK45978.pdf">PDF version of this page</a> (190K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#spg3a.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#spg3a.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#spg3a.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#spg3a.Genetically_Related_Allelic_Disord" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#spg3a.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#spg3a.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#spg3a.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#spg3a.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#spg3a.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#spg3a.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#spg3a.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=51062[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">ATL1</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Variations in ClinVar</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=NBK45978+AND+genereviews[submitter]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Variations from this GeneReview in ClinVar</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=2330536" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=2330536" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=2330536" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=2330536" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301339" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Spastic Paraplegia 4</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Spastic Paraplegia 4<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Parodi L, Rydning SL, Tallaksen C, Durr A. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301727" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Spastic Paraplegia 8</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Spastic Paraplegia 8<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Valdmanis PN, Meijer IA, Rouleau GA. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301286" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Spastic Paraplegia 7</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Spastic Paraplegia 7<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Casari G, Marconi R. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301389" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Spastic Paraplegia 11</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Spastic Paraplegia 11<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Stevanin G. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301565" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Central Core Disease</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Central Core Disease<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Malicdan MCV, Nishino I. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20862796" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20862796" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e042b3939a66ee2bac6618f">Spastic Paraplegia 3A - GeneReviews®</a><div class="ralinkpop offscreen_noflow">Spastic Paraplegia 3A - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T22:38:33-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal103&amp;ncbi_phid=CE8AC3E6E04243F10000000002F20129&amp;ncbi_session=CE8AC3E6E042B391_0754SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK45978%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK45978&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK45978/&amp;ncbi_pagename=Spastic Paraplegia 3A - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8AC3E6E042B391_0754SID /projects/books/PBooks@5.22 portal103 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>